Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA (canagliflozin) is Being Stopped Early for Positive Efficacy Findings

RARITAN, N.J., July 16, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) clinical trial, evaluating the efficacy and safety of INVOKANA® (canagliflozin) versus placebo when used in addition to standard of care for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), is being stopped early based on the achievement of pre-specified efficacy criteria.

read more